GlassScriptPhysician profile
Andres S Enriquez
NPI 1982616173
$10,645.14
in general payments reported to CMS, 2019-2025
35 companies · $2,213 in 2025
The $2,213 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $1,394 · 2021: $1,448 · 2022: $886 · 2023: $590 · 2024: $2,990 · 2025: $2,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800 · Consulting Fee: $2,060 · Travel and Lodging: $848 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,799.68 |
| Consulting Fee | $2,060.00 |
| Travel and Lodging | $848.46 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,127.90 | 2019-2025 | Ensite Precision, Freestyle Libre 3, Ensite |
| Lilly USA, LLC | $1,004.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $724.11 | 2021-2025 | |
| Novo Nordisk INC | $680.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $542.10 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.02 | 2019-2025 | Jardiance |
| Pfizer INC. | $402.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $383.80 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $282.90 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $278.01 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $209.92 | 2019-2023 | |
| Allergan, INC. | $209.33 | 2019-2020 | |
| Amgen INC. | $199.52 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi Pasteur INC. | $150.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $116.02 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $82.96 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $79.13 | 2024-2025 | |
| Horizon Therapeutics Plc | $74.33 | 2019 | |
| Amarin Pharma, INC. | $71.39 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $60.87 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $60.09 | 2019-2021 | |
| Genentech USA, INC. | $55.51 | 2021-2022 | |
| Esperion Therapeutics, INC. | $50.48 | 2024-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $50.21 | 2021 | |
| Dexcom, INC. | $46.67 | 2022-2025 | Dexcom G6 Transmitter |
| Endogastric Solutions, INC | $44.06 | 2019 | |
| Shield Therapeutics INC | $40.25 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $34.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $34.45 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $29.04 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.90 | 2020 | |
| Melinta Therapeutics, LLC | $25.08 | 2019 | |
| Insulet Corporation | $24.77 | 2023 | Omnipod |
| Alkermes, INC. | $15.65 | 2025 | Vivitrol |
| Exact Sciences Corporation | $13.81 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Enriquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.